argenx SE (NASDAQ:ARGX) Receives $525.42 Consensus Price Target from Analysts

Shares of argenx SE (NASDAQ:ARGX) have been given an average rating of “Moderate Buy” by the twenty-one brokerages that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $525.42.

Several equities research analysts have issued reports on ARGX shares. Wells Fargo & Company boosted their price target on shares of argenx from $478.00 to $542.00 and gave the company an “overweight” rating in a report on Monday, June 24th. Morgan Stanley lowered their target price on shares of argenx from $515.00 to $510.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 28th. Bank of America restated a “buy” rating and set a $607.00 price target (up previously from $535.00) on shares of argenx in a research note on Monday, June 24th. JMP Securities lowered their price objective on argenx from $471.00 to $468.00 and set a “market outperform” rating on the stock in a research note on Friday, May 10th. Finally, HC Wainwright restated a “buy” rating and set a $448.00 target price on shares of argenx in a research report on Monday, June 24th.

Hedge Funds Weigh In On argenx

Large investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its position in argenx by 49.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after purchasing an additional 1,830,651 shares during the last quarter. Artisan Partners Limited Partnership increased its stake in shares of argenx by 12.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,174,477 shares of the company’s stock valued at $1,207,666,000 after buying an additional 346,178 shares during the period. Janus Henderson Group PLC increased its stake in shares of argenx by 24.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock valued at $872,690,000 after buying an additional 439,889 shares during the period. Capital World Investors raised its position in shares of argenx by 37.0% during the fourth quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock worth $746,099,000 after acquiring an additional 530,181 shares during the last quarter. Finally, Avoro Capital Advisors LLC lifted its stake in shares of argenx by 0.3% during the first quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock valued at $487,609,000 after acquiring an additional 3,900 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Stock Performance

NASDAQ ARGX opened at $435.29 on Monday. argenx has a twelve month low of $327.73 and a twelve month high of $550.76. The stock has a market cap of $25.87 billion, a PE ratio of -76.91 and a beta of 0.64. The firm has a 50-day simple moving average of $386.70 and a 200 day simple moving average of $386.09.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Monday, May 13th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.33). The firm had revenue of $412.51 million during the quarter, compared to the consensus estimate of $404.03 million. argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. During the same quarter in the prior year, the business posted ($0.52) EPS. Research analysts forecast that argenx will post -2.88 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.